Andrea Fagiolini, MD, is Chairman, Chief of Medical Services, and Residency Training Director of the Department (DAI) of Mental Health and Division of Psychiatry, University of Siena School of Medicine, Italy. He received his medical training at the University of Pisa School of Medicine, Italy. After completing his psychiatric residency at the University of Modena, Italy, he spent more than 10 years at the University of Pittsburgh Medical School, USA, where he served as Associate Professor of Psychiatry and Medical Director of the Bipolar Disorder Center and the Depression and Manic Depression Prevention Program. His research interests focus on the treatment of mood and psychotic disorders, suicidality, functional impairment, and quality of life. He is the author or co-author of over 400 books and peer-reviewed articles serves on the editorial Board of several peer reviewed international journals.
Alessandro Cuomo, MD-PhD, is an assistant professor at the University of Siena School of Medicine. He has published several papers in international peer reviewed journals, primarily focusing on the treatment of mood and psychotic disorders. He has been co-investigator in several research studies, including phase 3 and phase 4 clinical trials. His research interests and publications have primarily focused on the treatment of major depressive and bipolar disorders, including pharmacological treatment during pregnancy, sequential treatment of mood disorders, role of vitamin D and microbiome in psychiatric diseases.
Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto.
Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022 and 2023 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has authored/co-authored more than 1000 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavours which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders. Dr. McIntyre has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. Dr. McIntyre’s research has also extended into public health and implementation research at the population-based level.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada. Additionally, Dr. McIntyre was awarded the Colvin Prize for Outstanding Achievement in Mood Disorders Research from the Brain and Behavior Research Foundation in 2023.
Dr. McIntyre has also contributed extensively to clinical practice guidelines. For example, Dr. McIntyre is the lead author the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. In addition, Dr. McIntyre is also the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders as well as the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
